Citius Pharmaceuticals (CTXR) AI Stock Analysis

• Market Cap: $9.77M
• Dividend Yield: N/A
• Average Volume (3M): 3.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: N/A
• EPS Growth: 8.99%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -1.27
• Shares Outstanding: 11,174,466
• 10 Day Avg. Volume: 11,293,197
• 30 Day Avg. Volume: 3,855,245
• PEG Ratio: -13.79
• Price to Book (P/B): 42.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -155.81
• Enterprise Value/Market Cap: 447.96
• Enterprise Value/Revenue: 14.04K
• Enterprise Value/Gross Profit: -41.73K
• Enterprise Value/Ebitda: -26.61
• 1Y Price Target: $5.00
• Price Target Upside: 474.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 38 Underperform
• Price Target: ―

Citius Pharmaceuticals' overall stock score reflects the challenging financial performance and bearish technical indicators. The company's ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock's downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.

Positive Factors

Clinical Trials

Mino-Lok has the potential to salvage the catheter with a 100% salvage rate in Phase 2b.

Regulatory Approval

The FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.

Reimbursement

Citius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.

Negative Factors

Financial Constraints

Citius Pharma reported a net loss with very limited cash, indicating the need to raise capital soon.

Financial Health

The company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.

Regulatory Timeline

Completing the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Citius Pharmaceuticals Business Overview & Revenue Model

Company Description

Citius Pharmaceuticals, Inc. (CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care, prescription products, and unique therapies using innovative delivery mechanisms. The company operates primarily in the biotechnology and healthcare sectors, leveraging its expertise to address unmet medical needs by developing and enhancing existing drug formulations.

How the Company Makes Money

Citius Pharmaceuticals generates revenue through the development and commercialization of its pipeline of proprietary and collaborative pharmaceutical products. Key revenue streams include sales from FDA-approved products, licensing agreements, and strategic partnerships with other pharmaceutical companies. Citius focuses on advancing its clinical-stage products to commercialization, where it can earn revenues from product sales and royalties. Significant partnerships with healthcare organizations and research institutions also contribute to its earnings by facilitating product development and expanding market reach. Additionally, the company may receive milestone payments based on achieving specific regulatory or commercial objectives.

Citius Pharmaceuticals Financial Statement Overview

Summary

Citius Pharmaceuticals faces significant challenges typical of early-stage biotech firms, with ongoing losses and reliance on external financing. The company's financial health is stable in terms of assets and equity, but cash burn and lack of revenue generation remain critical concerns. Future success hinges on achieving revenue growth and improving operational efficiency.

Income Statement

Citius Pharmaceuticals shows a challenging income statement with negative gross profit and net income, primarily due to high operating expenses. The company has not yet generated significant revenue, with the most recent TTM (Trailing-Twelve-Months) total revenue being minimal. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies. Revenue growth is difficult to assess due to negligible sales figures.

Balance Sheet

The balance sheet reflects a moderate financial structure with a reasonable debt-to-equity ratio and positive equity. However, the company has been relying heavily on equity financing, as evidenced by frequent capital raises, which could dilute shareholder value. The equity ratio remains strong, indicating a solid foundation of assets relative to liabilities.

Cash Flow

Citius Pharmaceuticals has a negative free cash flow and operating cash flow, highlighting cash burn issues typical for biotechnology companies in development phases. The cash flow from financing activities indicates reliance on external funding. There is no positive free cash flow growth, and the operating cash flow to net income ratio suggests inefficiencies in converting income to cash.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
155.93K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-104.92K	0.00	-194.32K	-179.68K	-164.87K	-152.36K
	EBIT
-42.69M	-42.00M	-36.73M	-33.32M	-23.53M	-17.71M
	EBITDA
-42.53M	-38.64M	-31.77M	-32.88M	-22.88M	-17.38M
	Net Income Common Stockholders
-39.68M	-39.43M	-32.54M	-33.64M	-23.13M	-17.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.10M	3.25M	26.48M	41.71M	70.07M	13.86M
	Total Assets
120.70M	116.65M	103.61M	114.00M	142.43M	43.77M
	Total Debt
204.57K	262.87K	481.25K	678.23K	855.47K	1.35M
	Net Debt
-895.51K	-2.99M	-26.00M	-41.03M	-69.22M	-12.51M
	Total Liabilities
51.78M	42.55M	12.18M	10.57M	9.65M	10.10M
	Stockholders Equity
65.41M	70.08M	90.83M	102.83M	132.18M	33.67M
Cash Flow		Free Cash Flow
-26.79M	-28.20M	-29.06M	-28.36M	-64.26M	-16.93M
	Operating Cash Flow
-26.79M	-28.20M	-29.06M	-28.36M	-24.25M	-16.93M
	Investing Cash Flow
-5.00M	-5.00M	0.00	0.00	-40.01M	-1.83K
	Financing Cash Flow
12.55M	9.97M	13.83M	0.00	120.47M	22.90M

Citius Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.87
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 0.87 is above the 20-day moving average (MA) of 0.84, above the 50-day MA of 0.86, and below the 200-day MA of 4.71, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 14.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.

Citius Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
SABS	49 Neutral	$15.89M	―	-92.35%	―	-85.48%	45.13%
MRKR	44 Neutral	$18.10M	―	-97.30%	―	-3.23%	38.05%
PSTV	41 Neutral	$10.27M	―	249.03%	―	-14.43%	16.04%
CTXR	38 Underperform	$9.77M	―	-60.06%	―	―	8.99%
SPRB	35 Underperform	$3.15M	―	-135.33%	―	-51.32%	-1.76%
MTVA	33 Underperform	$14.34M	―	-339.64%	―	―	-75.88%